India's Pharma Regulator Tasked with Resolving MSME GMP Compliance Crisis Ahead of January Deadline

Spread the Message

Read Time:3 Minute, 51 Second

Union Health Minister JP Nadda has directed the Central Drugs Standard Control Organisation (CDSCO) and Department of Pharmaceuticals (DoP) to develop a workable solution addressing industry concerns over the revised Schedule M Good Manufacturing Practices (GMP) norms, just weeks before the December 31, 2025, compliance deadline for small and medium enterprises (MSMEs).

This intervention follows urgent meetings with stakeholders, including RSS-affiliated Laghu Udyog Bharti (LUB), amid fears that strict enforcement could shutter thousands of units and disrupt medicine supplies.

Background on Revised Schedule M

The revised Schedule M, notified on December 28, 2023, under the Drugs and Cosmetics Rules, 1945, upgrades GMP standards to align India’s pharmaceutical manufacturing with World Health Organization (WHO) guidelines and international benchmarks like PIC/S PE009. Key enhancements include mandatory Pharmaceutical Quality Systems (PQS), Quality Risk Management (QRM), equipment validation, product quality reviews (PQR), self-inspection protocols, sanitation hygiene, complaint handling, and computerized storage systems for data integrity.

Large manufacturers (turnover > ₹250 crore) faced a six-month compliance window from June 2024, while MSMEs received phased extensions culminating in December 31, 2025, after submitting upgrade plans via Form A. These norms mandate controlled premises, advanced air handling, and robust recall systems to prevent defective drugs, responding to past incidents like contaminated cough syrups linked to child deaths in India and Uzbekistan.

India’s 10,500 drug units—80% MSMEs—produce affordable generics for domestic use and exports to low- and middle-income countries, making compliance pivotal for global trust.

Industry Concerns and Recent Developments

Pharma MSMEs argue the norms demand costly upgrades in infrastructure, training, and technology, straining finances amid cash crunches. A LUB pan-India survey revealed 25% of units seek extension to 2026, with over 20 associations warning of 5,000-6,000 closures, job losses, medicine shortages, and price hikes.

Nadda held discussions on January 10 and 16, 2026, assuring a balanced approach; industry sources anticipate announcements on extensions or relaxations this week. Despite this, DCGI Dr. Rajeev Raghuvanshi insisted in December 2025 that norms enforce as scheduled from January 1, 2026, prioritizing patient safety over further delays, having already closed 40% of non-compliant units.

Key Changes and Compliance Challenges

Aspect	Pre-Revised Schedule M	Revised Schedule M Requirements
Quality System	Basic GMP checklist	Full PQS with QRM and PQR
Premises/Equipment	Minimal specs	Validation, qualification, HVAC controls
Documentation	Manual records	Computerized systems, data integrity
Inspection	Periodic audits	Enhanced self-inspection, change control
Scope	Manufacturing only	Includes recalls, complaints, hygiene

MSMEs, often lacking WHO-GMP certification (only ~2,000 hold it), face hurdles in retrofitting facilities while competing globally. Partial compliance requests have been submitted, but regulators emphasize totality for quality reset.

Expert Perspectives

“The revised Schedule M is a GMP reset elevating senior management accountability for risks, deviations, and CAPA—essential for narrowing the India-global gap,” notes a regulatory consultant familiar with CDSCO inspections.

DCGI Raghuvanshi stated, “While industry calls for extension overlook quality risks to patients, we’ve shut non-compliant units; this is the last chance.” An industry executive countered, “Without workable timelines, exports to ROW markets suffer, hiking prices for essential drugs.”

Pharma experts like those from Pharmadocx highlight benefits: “High-quality, safe drugs via validation and self-inspection will boost India’s reputation.”

Public Health Implications

Stricter GMP promises safer medicines, reducing contamination risks and enhancing export reliability—critical as India supplies 20% of global generics. For consumers, this means fewer adverse events, though short-term disruptions could affect availability of affordable drugs.

A balanced solution might include phased rollouts or subsidies, preventing supply gaps while upholding standards; failure risks medicine insecurity in dependent nations. Long-term, compliance fosters innovation, but MSME support is key to avoiding monopolies by large firms.

Limitations and Counterarguments

Critics note uneven enforcement capacity at CDSCO and potential overreach on small units already struggling post-COVID. Price controls via NPPA limit hikes (10% cap for non-scheduled drugs), mitigating inflation fears. Only ~20% MSMEs may need full overhauls if partial upgrades suffice, per lobby proposals.

Yet, regulators counter that delays perpetuate substandard production, citing Uzbekistan deaths as wake-up calls.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.